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Abstract
Background: Synchronous development of primary hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC) in different sites of the liver have rarely been reported before. The purpose of this
study is to investigate the clinicopathological characteristics of synchronous double cancer of HCC and ICC.
Case presentation: A 56-year-old Chinese man without obvious liver cirrhosis was preoperation diagnosed with
multiple HCC in segments VI (SVI) and VII (SVII) by the abdominal computed tomography (CT) and contrast-enhanced
ultrasonography (CEUS). We performed hepatic resection of both segments. The tumors in SVI and SVII were
pathologically diagnosed as ICC and HCC, respectively. Immunohistochemically, the HCC in SVII was positive for
HepPar-1 and negative for CK19, while the ICC in SVI tumor was positive for CK19 and negative for HepPar-1.
Interestingly, the immunohistochemical results also showed that the classic hepatic progenitor cell (HPCs) markers
CD34 and CD117 were both positive of the two tumors. The patient still survived and at a 1-year follow-up did not
show evidence of metastasis or new recurrent lesions. We speculate that the two masses may have originated from
HPCs based on the findings of this patient.
Conclusions: Synchronous development of HCC and ICC is very rare with unique clinical and pathological features.
The correct preoperative diagnosis of double hepatic cancer of HCC and ICC is difficult. Hepatitis B virus (HBV) and
hepatitis C virus (HCV) infection were both the independent risk factor to the development of double liver cancer.
Hepatic resection is the preferred and most effective treatment choice. The prognosis of synchronous occurrence of
double hepatic cancer was poorer than for either HCC or ICC, and the origin of it needs further study.
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Background
Primary liver cancers are divided into hepatocellular
carcinoma (HCC), intrahepatic cholangiocarcinoma
(ICC), and combined hepatocellular carcinoma and chol-
angiocarcinoma (cHCC-CC) according to the histo-
logical type. HCC and ICC are the two most common
primary liver cancers. There are reports of cancers with
cHCC-CC in a single tumor [1, 2]; however, double pri-
mary liver cancer comprising different primary hepatic tu-
mors in the same liver is exceedingly rare [3–5]. We
herein present a patient who underwent hepatic resection
for double primary hepatic cancer without a background
of obvious liver cirrhosis. We also review the current lit-
erature of related clinicopathological features and investi-
gate the origin of double primary hepatic cancer.
Case presentation
A 56-year-old man was admitted to our hospital with
the chief complaint of lumbago in the right side for
1 week. He had a history of splenectomy and blood
transfusions due to spleen rupture. However, he had no
history of exposure to any hepatotoxic chemicals and no
family history of liver disease. Physical examination find-
ings upon admission were normal. Laboratory examin-
ation produced the following results: white blood cell
count, 6.61 × 109/l; red blood cell count, 3.70 × 1012/l;
hemoglobin, 120 g/l; albumin, 39.811 g/l; globulin,
26.81 g/l; total bilirubin, 9.59 μmol/l; and prothrombin
time, 14.9 s. The alanine aminotransferase, aspartate
aminotransferase, and lactate dehydrogenase levels
were within normal ranges. Hepatitis B virus-related
antigen and antibody were negative with the exception
of hepatitis B e antibody (HBeAb) and hepatitis B core
antibody (HBcAb). Anti-HCV antibody was negative.
The carbohydrate antigen 19-9, α-fetoprotein, and
carcinoembryonic antigen levels were 166.77 U/ml,
7.0 ng/ml, and 0.98 ng/ml, respectively. Preoperative
abdominal computed tomography (CT) and contrast-
enhanced ultrasonography (CEUS) provided vivid im-
ages of two separate lesions with different contrast
features in segment VI (SVI, 4.5 × 4 cm in size) and
segment VII (SVII, 6 × 5 cm in size) (Figs. 1 and 2),
suggesting tumors of different origins. The patient
was diagnosed with double primary hepatic cancer
(hepatocellular carcinoma and intrahepatic cholangio-
carcinoma) and underwent partial liver hepatectomy
and cholecystectomy. The resected specimen contained a
soft, red, focal hemorrhage tumor (7 × 5.5 × 5.5 cm in size)
in SVII, and a hard, off-white tumor (4.5 × 4 × 4 cm in
size) in SVI (Fig. 3). The SVII tumor was histologically
confirmed as a typical moderately differentiated HCC with
a trabecular pattern. The SVI tumor was pathologically
diagnosed as a poorly differentiated ICC with mucin-pro-
ducing glands (Fig. 4). Immunohistochemically, the
SVII tumor was positive for HepPar-1 and negative for
CK19, and the SVI tumor was positive for CK19 and
negative for HepPar-1. We further examined the HPCs
markers immunohistochemically, and the results
showed that the classic HPCs markers CD34 and
CD117 were both positive of the two tumors (Fig. 5).
The hepatic tissue adjacent to the tumors showed no
liver cirrhosis. According to the histological findings,
the liver tumors in this patient were diagnosed as a
double primary liver cancer. The postoperative course
was uneventful, and he was discharged on the seventh
postoperative day. The patient survived and at 1-year
Fig. 1 Computed tomography (CT) imaging of the patient with a double hepatic cancer of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma. Abdominal unenhanced CT showed two separate low-density tumors, in SVII (A1, large arrow) and SVI (A2, small arrow) of the
liver. On contrast-enhanced dynamic CT, the SVII (B1, large arrow) tumor was enhanced, and the SVI (B2, small arrow) tumor showed peripheral
enhancement during the arterial phase. Followed by wash-out during the portal venous phase (C1, C2) and the delayed phase (D1, D2): during the
portal venous phase, the SVII (C1, large arrow) and SVI (C2, small arrow) tumors showed negative enhancement, and the density of SVII tumor rapidly
decreased. During the delayed phase, the density of SVII (D1, large arrow) tumor further decreased, and the SVI (D2, small arrow) tumor showed slightly
centripetal enhancement
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follow-up did not show evidence of metastasis or new
recurrent lesions.
Discussion
Combined hepatocellular carcinoma and cholangiocarci-
noma (cHCC-CC) is a rare primary liver tumor (PLC)
that contains both hepatocellular carcinoma (HCC) and
cholangiocarcinoma (ICC) and only accounts for 0.4 to
14.2 % of PLCs [6]. Although Wells reported cHCC-CC
in 1903, the pathological histology, biological behavior,
clinical characteristics, and prognosis of cHCC-CC are
still lacking compared with those HCC and ICC [7–9].
Currently, there is no uniform pathology classification of
cHCC-CC, and there are mainly two types of classifica-
tion. Allen and Lisa [10] first divided cHCC-CC into
three types: type A (HCC and ICC grow independently
in different parts of the same liver, but have clear bound-
aries); type B (HCC and ICC originate from different
cells and mingle as they grow; however, there are still
certain boundaries between the two populations); and
type C (HCC and ICC are completely integrated within
the same tumor). Type C tumors are widely accepted as
true cHCC-CC [11]. However, Goodman [12] put
forward another pathological classification system that
differed from that of Allen in 1985 and included type I
(collision), type II (transitional), and type III (fibrolamel-
lar) tumors. Based on the classification, we defined the
liver tumors in our patient as type A or type I.
The cellular origin of double primary hepatic cancer is
still unclear. Several studies have been proposed for such
tumors. Some reports have shown that the cells which
have already differentiated into both hepatocytes and
choangiocytes before malignant transformation. Others
revealed that activated HPCs were considered to be
Fig. 2 There were different CEUS finding features in two separate liver lesions
Fig. 3 The cut surface of the resected specimen showed two tumors,
one in SVII (upper arrow) is HCC and one in SVI (lower arrow) is ICC
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Fig. 4 Histological findings of the liver tumors (hematoxylin-eosin staining, ×100). a The SVII tumor was pathologically diagnosed as a moderately
differentiated hepatocellular carcinoma (HCC) (with nodular, trabecular). b The SVI tumor was pathologically diagnosed as a poorly differentiated
cholangiocellular carcinoma (ICC) (with mucin-producing glands)
Fig. 5 a, b Immunohistochemical staining for CK19. This was positive in the SVI tumor (ICC) a and negative in the SVII tumor(HCC). b c, d
Immunohistochemical staining for HepPar I. This was negative in the SVI tumor c and positive in the SVII tumor. d e, f Immunohistochemical
staining for hepatic progenitor cell marker CD34. The SVI and SVII tumor were both positive for CD34. g, h Immunohistochemical staining for
hepatic progenitor cell marker CD117. The SVI and SVII tumor were both positive for CD117. a–h ×100
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involved in carcinogenesis; HPCs have the potential to
differentiate into either hepatocytes or cholangiocytes
[4].
HPCs are thought to reside in the canals of Hering
and can be activated and contribute to liver self-renewal
and repair in response to liver injury by proliferating and
differentiating towards both hepatocytes and biliary epi-
thelial cells [13]. HPCs play an important role in the de-
velopment and prognosis of the liver cancer [14–18].
There are a great number of studies revealing that HPCs
are one probable origin of liver cancer. Reya [19] sug-
gested that there is an affinity between HPCs and pri-
mary liver cancer according to the hypothesis of cancer
stem cells and biological behaviors of HPCs. The fact
that many liver tumors contain a mixture of mature cells
and cells phenotypically similar to HPCs is the proof
that HPCs may be possible to give rise to liver cancers
[20]. HPCs are long-life cells that they are competent of
surviving long enough to store up DNA damages, and
the mutations are shared by lots of inferiors of the mu-
tant progenitor cells; they become tumors more easily
than other cell types [21, 22]. Research shows that HPCs
contain the potential to differentiate into either hepato-
cytes or cholangiocytes, which also suggests that liver tu-
mors may originate from HPCs [23]. HPCs have a
powerful self-renewal capacity and rapid proliferation
potential when the adult hepatocytes are heavily and
continuously impaired beyond the ability to self-repair
which dramatically increases the risk of progenitor cell
mutations and is an indispensable approach for malig-
nant transformation [24].
HPCs markers are used to identify the HPCs; there
are a larger number of HPCs markers, and CD34 and
CD117 are two of the classic human HPCs markers
[25, 26]. We performed the immunohistochemical
analysis of CD34 and CD117 to examine whether the
two tumors arose from the HPCs in our study. The result
showed that CD34 and CD117 were both positive of the
two tumors, so we conclude that the two nodules com-
posing the double primary hepatic cancer herein reported
may originated from the hepatic progenitor cell.
Double hepatic cancer of HCC and ICC is rarely en-
countered in clinical practice, and according to the
retrospective analysis of Watanable [27], the incidence
of double primary liver cancer was 0.54–0.70 % of PLCs,
and the male to female ratio of double cancer was 10:1.
The average age of double cancer patients was 67, the
rates of HBV and HCV infection were 9.1 and 72.7 %,
respectively, and cirrhosis was observed in 36.4 % of pa-
tients. The rates of patients positive for expression of
AFP and CA19-9 were 75.8 and 57.1 %, respectively. In
contrast, Cao [28] retrospectively summarized the clin-
ical data of 35 patients with simultaneous double cancer
of HCC and ICC in his study, and the results showed
that the incidence of double hepatic cancer was 0.25 %,
the male to female ratio was 4:1, the average age of pa-
tients was 50 years old, the HBV and HCV infection
rates were 100 and 60 %, respectively, all of the patients
had cirrhosis, and simultaneously elevated AFP and
CA19-9 levels were observed in 28.6 % of patients. It has
been suggested that the background of double cancer is
distinctly different from that of the cHCC-CC. In our
study, the 56-year-old male had a history of HBV infec-
tion; however, this was not associated with obvious cir-
rhosis of the liver, and his AFP and CA19-9 levels were
normal upon serological examination.
Surgical resection remains the preferred and most ef-
fective treatment option for double primary liver cancer
and is especially suitable for patients without cirrhosis of
the liver [29, 30]. However, commonly combined liver cir-
rhosis has the risk of serious complications, so strict
choice of patients before surgery is important, and general
physical condition should be considered, for example, any
pre-existing cirrhosis and tumor extent [31, 32]. Recently,
aggressive treatments including liver transplantation have
been used on patients as a radical approach [33]; however,
the long-term curative effect of liver transplantation need
to be further studied. Transcatheter arterial chemoemboli-
zation (TACE), percutaneous ethanol injection (PEI) and
radiofrequency ablation (RFA) are widely used for unre-
sectable HCC and patients with recurrence after resection.
However, the double hepatic tumor contains more fibrous
tissue and fewer vascular components than HCC, and
therefore, the therapeutic effect of TACE or PEI is limited
[34]. In our case, we performed hepatic resection on the
patient. The patient survived and at 1-year follow-up did
not show evidence of metastasis or new recurrent lesions.
The prognosis of double primary cancer varies among
different studies. However, the prognosis of double
primary cancer has commonly been recognized to be
poorer than for either HCC or ICC due to metastasis
[30]. Cao retrospectively studied the clinical characteris-
tics of 35 cases of double primary cancer and revealed
that tumor recurrence developed in 77.1 % of patients,
and distant metastases were detected in 20 % of patients
after partial hepatectomy. The median overall survival
(OS) was 18 months, and the 1-year, 3-year, 5-year OS
rates were 60.0, 28.9, and 23.1 %, respectively [28].
Conclusions
In summary, we have reported a rare case of double
primary liver cancer verified by pathological and immu-
nohistochemical analysis. The clinical information re-
mains inconclusive because of its rarity. There are
many aspects of double primary liver cancer that differ
from HCC or ICC. The preoperatively diagnosis is
more difficult, the therapeutic effect remains unclear,
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the origin of it need further study, and the prognosis is
poorer. We need to pay more attention to double pri-
mary liver cancer, and we need to accumulate more
cases for further research.
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